IL6 and rheumatoid arthritis: While tocilizumab significantly reduces the disease activity of RA by effectively inhibiting IL-6 signal transduction and the subsequent anti-inflammatory response [49,50], the increase in blood levels of free IL-6 may result in high IL-6 exposure to organs during drug treatment.